Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations

被引:43
作者
Arnadottir, M [1 ]
Gudnason, V
Hultberg, B
机构
[1] Natl Univ Hosp Reykjavik, Dept Med, IS-101 Reykjavik, Iceland
[2] Iceland Heart Assoc Heart Prevent Clin, Reykjavik, Iceland
[3] Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden
关键词
cysteine; folate; glutathione; haemodialysis; homocysteine; renal failure;
D O I
10.1093/ndt/15.4.524
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Hyperhomocysteinaemia is highly prevalent among haemodialysis patients and may contribute to their increased cardiovascular risk. Treatment with pharmacological doses of folic acid lowers the plasma homocysteine concentration in these patients. The purpose of the present study was to expand the knowledge about such treatment by testing the effects of stepwise increases in the dose of folic acid on the concentrations of plasma and red blood cell folate as well as the total plasma concentrations of homocysteine (tHcy), cvsteine (tCys), and glutathione (tGSH) in patients on chronic hemodialysis. Methods. Fourteen stable haemodialysis patients completed the study which consisted of four consecutive periods, each of 6 weeks duration: (i) no treatment with folic acid (control period); (ii) 5 mg of folic acid three times per week (15 mg/week); (iii) 5 mg of folic acid daily (35 mg/week); (iv) 10 mg of folic acid daily (70 mg/week). Results. Neither plasma or red cell folate nor plasma aminothiol concentrations changed significantly during the control period. The mean red cell folate concentration doubled during the administration of folic acid at the dose of 15 mg/week but at higher doses the further rise was only marginal. The mean folate concentration in plasma increased steeply especially at the higher doses of folic acid. During treatment with 15 mg/week of folic acid, tHcy fell by a mean of 36%, tGSH increased by a mean of 34%, but tCys was unaffected. Increases in the dose of folic acid did not augment these responses. Conclusions. The maximal effect on tHcy seemed to be obtained already at the lowest given dose of folic acid (15 mg/week). At that dose, the red blood cells approached folate saturation, which may reflect the situation in other cells that participate in homocysteine metabolism and explain why further increases in the dose of folic acid are not effective from a tHcy-lowering point of view.
引用
收藏
页码:524 / 528
页数:5
相关论文
共 28 条
  • [1] ANDERSSON A, 1993, CLIN CHEM, V39, P1590
  • [2] ARNADOTTIR M, 1993, CLIN NEPHROL, V40, P236
  • [3] SHORT-TERM BETAINE THERAPY FAILS TO LOWER ELEVATED FASTING TOTAL PLASMA HOMOCYSTEINE CONCENTRATIONS IN HEMODIALYSIS-PATIENTS MAINTAINED ON CHRONIC FOLIC-ACID SUPPLEMENTATION
    BOSTOM, AG
    SHEMIN, D
    NADEAU, MR
    SHIH, V
    STABLER, SP
    ALLEN, RH
    SELHUB, J
    [J]. ATHEROSCLEROSIS, 1995, 113 (01) : 129 - 132
  • [4] High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
    Bostom, AG
    Shemin, D
    Lapane, KL
    Hume, AL
    Yoburn, D
    Nadeau, MR
    Bendich, A
    Selhub, J
    Rosenberg, IH
    [J]. KIDNEY INTERNATIONAL, 1996, 49 (01) : 147 - 152
  • [5] HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY
    BOSTOM, AG
    SHEMIN, D
    LAPANE, KL
    MILLER, JW
    SUTHERLAND, P
    NADEAU, M
    SEYOUM, E
    HARTMAN, W
    PRIOR, R
    WILSON, PWF
    SELHUB, J
    [J]. ATHEROSCLEROSIS, 1995, 114 (01) : 93 - 103
  • [6] A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES
    BOUSHEY, CJ
    BERESFORD, SAA
    OMENN, GS
    MOTULSKY, AG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13): : 1049 - 1057
  • [7] Chauveau P, 1996, MINER ELECTROL METAB, V22, P106
  • [8] Dennis VW, 1996, KIDNEY INT, V50, pS11
  • [9] Dierkes J, 1999, CLIN NEPHROL, V51, P108
  • [10] Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
    Fodinger, M
    Mannhalter, C
    Wolfl, G
    Pabinger, I
    Muller, E
    Schmid, R
    Horl, WH
    SunderPlassmann, G
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (02) : 517 - 523